Introduction: Although lung cancer is generally thought to be environmentally provoked, anecdotal familial clustering has been reported, suggesting that there may be genetic susceptibility factors. We systematically tested whether germline mutations in eight candidate genes may be risk factors for lung adenocarcinoma.
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide; it accounts for approximately 1.5 million deaths annually, and cigarette smoke is the major culprit in 85% to 90% of these cases. 1 Several pieces of evidence point to inherited factors potentiating the carcinogenic effects of cigarette smoke. Rare familial forms of lung cancer have been described; they show a pattern consistent with autosomal dominant inheritance. The EGFR T790M mutation, parkin RBR E3 ubiquitin protein ligase gene (PARK2) loss-of-function mutations, and in Asian populations, a single gain-of-function variant, Yes associated protein 1 gene (YAP1) R331W, have been associated with this phenotype. [2] [3] [4] In genome-wide association studies, common BRCA2, DNA repair associated gene (BRCA2) and checkpoint kinase 2 gene (CHEK2) variants have been found to have strong association with lung cancer risk. 5 For lung adenocarcinoma, there is also a well-documented association with polymorphisms in the telomerase reverse transcriptase gene (TERT). 6 Moreover, for two well-recognized familial cancer syndromes, Li-Fraumeni syndrome and ataxia-telengiectasia, lung cancer has been reported in smokers as well as in never-smokers.
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Methods
We sought to systematically examine whether the lung adenocarcinoma diagnosis enriches for individuals with germline pathogenic mutations in genes linked anecdotally to lung cancer risk, and, if they are present, to determine their prevalence. We focused on the lung adenocarcinoma histologic type because it has been reported to have familial clustering 2 largest group of never-smokers (approximately 15%). Importantly, although the somatic landscape of lung adenocarcinoma has been studied and reported, the germline exome data have not. 10 We focused on eight candidate genes that had been associated with lung cancer cases in rare Mendelian syndromes or in genome-wide association studies: ATM serine/threonine kinase gene (ATM), BRCA2, CHEK2, EGFR, PARK2, TERT, tumor protein p53 gene (TP53), and YAP1. After approval from the Database of Genotypes and Phenotypes data access committee, we designed an algorithm to download nontumor sequence data that were curated as part of The Cancer Genome Atlas (TCGA) lung adenocarcinoma project.
The filtering strategy is summarized in Figure 1 , and the detailed methods are included in the supplementary materials. Briefly, sequence data for the eight candidate genes we selected, from normal and nontumor tissue, were filtered for rare potentially disease risk alleles. We excluded common variants, defined as a minor allele frequency greater than 0.005, in each of the following: Single Nucleotide Polymorphism database, version 129; the Exome Variant Server; and the 1000 Genomes project. In a second filtering step to enrich for ultrarare variants, we filtered variants with frequencies greater than 0.00005 in the Exome Aggregation Consortium database (see Fig. 1 ). To exclude sequencing errors, we examined each of these remaining variants manually in an independently sequenced second normal and/or tumor sample; each of the variants had a minimum coverage depth of 20Â. These validated rare variants were then studied in a literature search and considered pathogenic if (1) they had been previously reported in familial cancer syndromes or (2) they were frameshift/nonsense mutations in known tumor suppressor genes. The remaining alterations were classified as variants of unknown significance), and their effect on protein function was examined in silico by using three prediction programs.
Results
At the time of analysis, there were 555 unique lung adenocarcinoma cases that had nontumor DNA sequenced. The characteristics for 497 of the patients in these cases were publicly available and are summarized in Table 1 . Their mean age was younger than that of the U.S. lung adenocarcinoma population (65.3 versus 70.0 years), and there was a female predominance (53% versus 49%). There were no pathogenic variants in CHEK2 or TERT, and we found no cases with the YAP1 R331W variant. However, 14 cases (2.5%) carried 12 unique pathogenic variants in five other genes: ATM (n ¼ 7), followed by TP53 (n ¼ 4), BRCA2 (n ¼ 1), EGFR (n ¼ 1) and PARK2 (n ¼ 1) ( Table 2 ). Seven mutations altered the reading frame or disrupted splicing, and all five missense mutations fell in highly conserved domains (Fig. 2) . All 11 ATM and TP53 missense mutations had been previously reported in ataxia telengiectasia or Li-Fraumeni syndrome, respectively (see Table 2 11-13 ). The BRCA2 frameshift mutation had been reported in a patient with ovarian cancer, 14 and EGFR T790M has been documented in familial lung adenocarcionma. 2, 15 PARK2 variants had been identified in familial lung cancer, and the frameshift we identified similarly predicted loss of function because of a premature stop codon. 4, 16 The prevalence of these variants in 60,706 individuals in the Exome Aggregation Consortium database was 0.0004%, indicating that the lung adenocarcinoma phenotype enriches for the rare heterozygous alleles we identified with an OR of 66 (95% confidence interval: 33-125, p < 0.0001 [chi-square test with Yates' correction, two sided]). We examined the clinical characteristics of mutation carriers. Of the 14 patients, 12 had published clinical data and a mean age of 62.7 years at diagnosis, which is slightly younger than the mean of 65.3 years for the cohort. Two patients were 41 and 49 years old, a finding suggestive of a genetic predisposition because only 7% of the entire TCGA cohort was younger than 50 years at diagnosis. Eight of the 12 patients were women (67%), and the two never-smokers were women. Three patients had a history of prior malignancy (25%), including a TP53 mutation carrier who had a prior thymus cancer (a Li-Fraumeni-associated cancer). The stage at presentation for these mutation carriers reflected the distribution of stage for the entire TCGA cohort (see Table 1 ), and all the patients with available data reported being white. The nonsynonymous mutation burden in tumors was available for the six patients for whom data had been available and published, and it matched what has been previously reported for the TCGA. 10 In the two neversmokers, with ATM and TP53 mutations, it was 22 and 71, respectively, and the four smokers with ATM and TP53 mutations had a mutation burden of 220 plus or minus 19 standard error of the mean, which was also comparable to the known mutation burden in lung adenocarcinoma. 17 Family history data were not collected for this cohort, as for the remainder of the TCGA. In addition to this subset of patients with pathogenic mutations, we identified 52 others with ultrarare or previously unreported variants (9.4%). These variants fell predominantly in BRCA2 (n ¼ 25 [48%]) and ATM (n ¼ 15 [29%]) (Supplementary Table 1 ). Twelve of these 52 mutations (23%), or 2% of this entire lung adenocarcinoma cohort, were predicted to be deleterious by three protein prediction programs, PolyPhen, PROVEAN, and SIFT (see Supplementary Table 1) .
Discussion
Lung cancer is considered environmentally driven, and smokers have at least a 20-fold increased risk. Although the rates of lung cancer have decreased in the United States as a result of successful prevention efforts, there has been no change in the number of cases in never-smokers and individuals with a history of relatively low exposure to cigarette smoke. 1 We found that 2.5% of unselected patients with lung adenocarcinoma carried pathogenic germline mutation in a cancerpredisposing gene. Given that lung adenocarcinoma has an annual incidence of 500,000 worldwide, this is a sizable and clinically relevant subset. The 2.5% prevalence we report may underestimate the overall frequency of germline mutations with a major effect on lung adenocarcinoma risk because our analysis relied on extremely stringent criteria for pathogenicity. If we also account for the ultrarare variants that were consistently predicted to be deleterious to protein function (see Supplementary Table 1) , the prevalence of germlinemutant cases could total 4.5%. Our data therefore add lung adenocarcinoma to the list of adult-onset cancers that includes a definable subset with germline mutations, similar to prostate and ovarian cancer. 18, 19 Further analysis of other large lung adenocarcinoma exome data sets will be important for estimating the overall prevalence of germline mutations in cancer-predisposing genes in this cancer.
There are potential clinical implications of the findings we report. First, patients with lung adenocarcinoma should be queried about a family history of all cancers, not just lung cancer, as their families may show clustering of Li-Fraumeni cancers (e.g., sarcoma, leukemia, breast cancer) or ATM-associated cancers. Second, as the use of next-generation panel testing continues to expand in clinical practice, variants that are suspicious for germline status (e.g., nearly 50% of reads) in the genes we identified should prompt consideration of a referral for genetic counseling and dedicated evaluation for germline testing. The most common mutant genes we identified involve DNA repair pathways, with ATM, TP53, and BRCA2 being most common. This observation is consistent with a carcinogenesis mechanism in to which cigarette smokeinduced genotoxic damage, or other environmental insults, are highly mutagenic against the background of defective DNA repair. 20 ATM polymorphisms have been associated with severe radiation-induced pneumonitis, illustrating another example in which the presence of a germline mutation may also inform the risk for specific clinical complications for an individual patient. 21 Importantly, germline defects in DNA repair genes cause sensitivity to poly(adenosine diphosphate-ribose) polymerase ribose polymerase inhibitors in advanced solid tumors such as prostate, ovarian, pancreatic, and breast cancer. [22] [23] [24] The data we report here suggest that a similar therapy approach may be effective in a small, genetically definable subset of patients with lung adenocarcinoma who carry germline mutations in DNA repair pathways.
